-
Dr. Fanning brings extensive experience in building infectious disease pipelines through in-house research and development and licensing.
-
As AstriVax's CBO, he will lead the company's business development, including partnerships, collaborations, and non-dilutive financings to advance the pipeline and create value for future funding rounds.
-
His initial focus will be on the company's vaccine candidate to treat chronic hepatitis B and form the future AstriVax vaccine pipeline.
Leuven, Belgium, March 19, 2024 – AstriVax is pleased to welcome Dr. Gregory Fanning as Chief Business Officer. Dr. Fanning joins CEO and co-founder Dr. Hanne Callewaardt, CTO Dr. Wilfried Dehlmans, CDO Dr. Matthew Peters and CFO Barbara Freitag, further strengthening the company's first-rate leadership team. .
Dr. Hanne KalevaldAstriVax co-founder and CEO said: “Greg has been one of our scientific and strategic advisors since almost the beginning, and we are very pleased to have him as part of our executive team. In his new role, he will be responsible for our business development, asset alliances, and , will lead new program evaluation, public-private partnerships, non-dilutive financing, and pipeline strategy. Greg will play a key role Our flagship treatment program for chronic hepatitis B, a condition associated with more than 800,000 deaths each year. A cure for this disease could come from combining AstriVax's approach with those of several other companies. Greg leverages his solid scientific background and business development experience to work with potential partners to help put the pieces of the puzzle together. ”
Dr. Gregory Fanning“Treatment of hepatitis B requires a combination of multiple approaches, and vaccines that induce strong CD4 and CD8 responses are key to unlocking the potential of complementary MOAs being explored in this field,” he said. “This is likely to be the case, and so far we have shown good reductions in virus measurements.” However, there are relatively few treatments available. ”
Greg has over 20 years of experience as a scientific leader for infectious disease programs in the pharmaceutical industry, leading companies to grow beyond seed funding, build pipelines, initiate scientific programs, and create value. We have supported you. Prior to joining AstriVax, he worked in the areas of gene therapy and small molecule drug discovery at Janssen Pharmaceuticals (now J&J Innovative Medicine). He took on leadership roles and built his R&D teams in Australia and Belgium, and China as an integral part of the establishment of the company's Shanghai R&D center. Most recently, he has served as an advisor to a handful of young, innovative biotechnology companies, covering a wide range of therapeutic platforms.
media contact
Dr. Hanne Callewaert, AstriVax CEO; info@astrivax.com.
About AstriVax
Founded in 2022, AstriVax NV aims to address global challenges in vaccinology with an innovative plug-and-play vaccine platform. The company develops new preventive and therapeutic vaccines that are easy to manufacture, reduce cold chain requirements, and provide broad, long-term protection against a variety of infectious diseases. AstriVax is funded by V-Bio Ventures, Fund+, Flanders Future TechFund managed by PMV, Thuja Capital, Ackermans & van Haaren, OMX Europe Venture Fund (Mérieux Equity Partners and Korys), BNP Paribas Fortis Private Equity, and Gemma Frisius of the University of Leuven. Fund.
AstriVax is located at the BioHub in Leuven. Learn more about. www.astrivax.com.
